^
Association details:
| Biomarker: | BRAF V600E + EGFR expression |
|---|---|
| Cancer: | Lung Adenocarcinoma |
| Drug: | Erbitux (cetuximab) (EGFR inhibitor) + Mekinist (trametinib) (MEK inhibitor) + Tafinlar (dabrafenib) (BRAF inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Cetuximab and Dabrafenib Plus Trametinib for Untreated Colonic Metastasis of BRAFV600E Mutant Primary Lung Adenocarcinoma with Signet Ring Cell Features: An Interesting and Rare Case Report
Published date:
09/26/2022
Excerpt:
We advised her to undergo genetic testing, and eventually a BRAF V600E mutation was identified….In this case, we found that EGFR expression was positive in the patient….Finally, a combination treatment with cetuximab (500 mg/m2 every two weeks) and dabrafenib (150 mg bid) plus trametinib (2 mg qd) was administered...The patient achieved a partial response.
DOI:
https://doi.org/10.2147/OTT.S375436
